Ballicules.com

Benzgalantamine

ZUNVEYL

What it isOral galantamine prodrug yielding cholinesterase inhibition; symptomatic treatment of Alzheimer dementia.

Why this oneIts prodrug design reduces direct intestinal exposure while preserving galantamine’s central action.

What limits itBradycardia, syncope, nausea, and weight loss remain possible; benefit is symptomatic and fades when treatment stops.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Mild-to-moderate dementia of the Alzheimer's typeAdult5 mg BID10 mg BID after ≥4 weeks15 mg BID

Titration Wait a minimum of 4 weeks at each dose level before increasing

Renal CrCl 9-59 mL/min: do not exceed 10 mg BID; CrCl <9: not recommended

Hepatic Moderate (Child-Pugh 7-9): do not exceed 10 mg BID; severe (10-15): not recommended; no adjustment for mild

Instructions

Cautions

Adverse reactions

Pregnancy No adequate human data; animal developmental toxicity (skeletal variations, decreased pup growth)

Lactation No human data on benzgalantamine or galantamine in milk

NO BOXED WARNINGS

Principal riskBradycardia; benefit is symptomatic only

Classes and tags

Clinical profile

Direct muscarinic antagonism0 / 4

Active metabolites

Mechanism of action: Benzgalantamine ballicule

Benzgalantamine ballicule: receptor binding, kinetics and half-life diagram

Open Benzgalantamine in the interactive console ↗

Memory aids: mascots and interaction avatars

Benzgalantamine ZUNVEYL mascot mnemonic cartoon
“Ben’s galantamine is a Sun veil”
baby blue theme → muscarinic
sky lantern → galantamine theme
Benzgalantamine Box: minimal PK interactions avatar
Box: minimal PK interactions

Open Benzgalantamine in the interactive console ↗